User:Mr. Ibrahem/Oxaprozin

Mr. Ibrahem/Oxaprozin
Clinical data
Trade names	Daypro, Dayrun, Duraprox, others
Other names	Oxaprozinum
AHFS/Drugs.com	Monograph
MedlinePlus	a693002
Pregnancy; category	C;
Routes of; administration	By mouth
Drug class	Nonsteroidal anti-inflammatory drug (NSAID)
Legal status
Legal status	AU: S4 (Prescription only); In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	95%
Protein binding	99%
Metabolism	Liver—65% oxidation and 35% glucuronic acid conjugation. 5% are active phenolic metabolites.
Elimination half-life	54.9 hours
Identifiers
	IUPAC name 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid;
Chemical and physical data
Formula	C18H15NO3
Molar mass	293.322 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)CCc1nc(c(o1)c2ccccc2)c3ccccc3;
	InChI InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21) ; Key:OFPXSFXSNFPTHF-UHFFFAOYSA-N ;
	(what is this?) (verify)

Oxaprozin, sold under the brand name Daypro among others, is a nonsteroidal anti-inflammatory drug (NSAID), used to treat inflammation in conditions such as osteoarthritis and rheumatoid arthritis.^[2] It is taken by mouth.^[2]

Common side effects include abdominal pain, stomach ulcers, gastrointestinal bleeding, nausea, poor kidney function, and itchiness.^[2] Other side effects may include liver problems, anaphylaxis, heart failure, myocardial infarction, and Stevens-Johnson syndrome.^[2] Use in the later part of pregnancy may harm the baby.^[2]

Oxaprozin was patented in 1967 and approved for medical use in 1983.^[3] In the United States it costs about 2.50 USD per 600 mg dose as of 2021.^[2] It is also available in Canada and Japan.^[1]

References[edit]

^ ^a ^b Society, Swiss Pharmaceutical (2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 768. ISBN 978-3-88763-075-1. Archived from the original on 10 November 2021. Retrieved 10 November 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Oxaprozin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 18 January 2021. Retrieved 10 November 2021.
^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 520. ISBN 9783527607495. Archived from the original on 2020-08-06. Retrieved 2020-10-17.

[IN2000-1] Society, Swiss Pharmaceutical (2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 768. ISBN 978-3-88763-075-1. Archived from the original on 10 November 2021. Retrieved 10 November 2021.

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Oxaprozin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 18 January 2021. Retrieved 10 November 2021.

[Fis2006-3] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 520. ISBN 9783527607495. Archived from the original on 2020-08-06. Retrieved 2020-10-17.

[1]

[2]

[3]